Glofitamab

Jun 10, 2025

A new era in lymphoma therapy began in 2023 when AbbVie and Genmab’s EPKINLY/TEPKINLY became the first CD20xCD3 bispecific antibody approved in the US for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). This groundbreaking approval marked a major milestone in immunother...

Feb 24, 2023

Cancer is the world’s second leading cause of death. Every year, 10 million people die from cancer. Cancer kills 70% of people in low-to-middle-income countries. Cancer is estimated to cost the global economy USD 1.16 trillion per year. Millions of lives could be saved annually by implementing resource-appropriate ...

May 31, 2022

Bristol-Myers Squibb’s Opdivo Gets FDA Approval for Esophageal Cancer The FDA has approved two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously untreated advanced Esophageal Cancer, encroaching on the territory belonging to Merck & Co’s rival Keytruda. The latest...